Price$22.51-0.25 (-1.10%)
01:30 PM07:45 PM
News · 26 weeks52-29%
2026-04-192026-10-11
Mix2590d
- Insider10(40%)
- SEC Filings7(28%)
- Other3(12%)
- Analyst3(12%)
- Earnings2(8%)
Latest news
25 items- ANALYSTFortrea upgraded by Deutsche Bank with a new price targetDeutsche Bank upgraded Fortrea from Hold to Buy and set a new price target of $25.00
- ANALYSTFortrea upgraded by Barclays with a new price targetBarclays upgraded Fortrea from Equal Weight to Overweight and set a new price target of $23.00
- PRFortrea Announces Date for Third Quarter 2026 Financial Results and Conference CallDURHAM, N.C., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization ("CRO"), today announced that it will release its third quarter 2026 financial results before the market opens on Thursday, October 29, 2026. The Company will host a conference call at 8:00 a.m. ET on that day to discuss the results. To participate in the conference call, participants should pre-register via the call registration link. All registrants will receive dial-in details and a unique PIN providing access to the live call. To avoid potential delays, participants are encouraged to join at least 10 minutes prior to the start of the call. The live we
- SECFortrea Holdings Inc. filed SEC Form 8-K: Leadership Update8-K - Fortrea Holdings Inc. (0001965040) (Filer)
- ANALYSTUBS initiated coverage on Fortrea with a new price targetUBS initiated coverage of Fortrea with a rating of Neutral and set a new price target of $22.00
- INSIDERSEC Form 4 filed by Chief Financial Officer Knoblauch Jason Fredrick4 - Fortrea Holdings Inc. (0001965040) (Issuer)
- PRFortrea Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)DURHAM, N.C., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization ("CRO"), today announced the granting of an inducement award of restricted stock units ("RSUs") and performance share units ("PSUs") on September 10, 2026, to five newly hired employees. Included in these awards were grants of employment inducement awards to Jason Knoblauch, the Company’s recently appointed Chief Financial Officer, as an inducement material to Mr. Knoblauch becoming a new employee of the Company. The grants were previously approved by the independent members of the Company’s Board of Directors. The awards consisted of (i) 106,755 PSUs tha
- INSIDERInterim CAO Russell Carrie Elizabeth converted options into 850 shares and sold $4,145 worth of shares (246 units at $16.85), increasing direct ownership by 34% to 2,384 units (SEC Form 4) (tax liability)4 - Fortrea Holdings Inc. (0001965040) (Issuer)
- INSIDERChief Operating Officer Morais Mark A. sold $53,061 worth of shares (3,149 units at $16.85) and converted options into 7,157 shares, increasing direct ownership by 5% to 81,794 units (SEC Form 4) (withholding obligation)4 - Fortrea Holdings Inc. (0001965040) (Issuer)
- PRFortrea to Participate in September Investor ConferencesDURHAM, N.C., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE), a leading global contract research organization ("CRO"), today announced that CEO Anshul Thakral, CFO Jason Knoblauch, and SVP of Investor Relations, Tracy Krumme will participate in the following conferences in September: Baird 2026 Global Healthcare Conference (NYC) Date: Tuesday, September 15, 2026Format: Fireside Chat & 1x1 and Group MeetingsTime: 2:00 -2:30 PM EDTWebcast: FTRE Baird Webcast Deutsche Bank 2026 Healthcare Summit (NYC) Date: Wednesday, September 16, 2026Format: 1x1 and Group Meetings RBC Pharma Services and Life Science Tools Virtual Conference Date: Tuesday, September 22, 2026Format: 1x1 and G
- SECFortrea Holdings Inc. filed SEC Form 8-K: Leadership Update8-K - Fortrea Holdings Inc. (0001965040) (Filer)
- PRFortrea to Acquire Clinical Pharmacology Unit and Bioanalytical Laboratory Operations from Worldwide Clinical TrialsHighlights Fortrea enters into a definitive agreement to acquire the Early Phase Services division of Worldwide Clinical TrialsIncludes a 60,000 sq. ft. GLP bioanalytical lab in Austin; a 200-bed GCP-compliant clinical pharmacology unit in San Antonio; and a biospecimen storage facility in Pflugerville, TexasEnables integrated execution of early-phase studies with large and small molecule bioanalytical capabilities, enhancing Fortrea’s ability to deliver faster, more integrated early clinical development solutions for simple and complex clinical studiesStrengthens Fortrea’s end-to-end clinical development platform, supporting customers from first-in-human studies through Phase IV and post-a
- INSIDERChief Operating Officer Morais Mark A. converted options into 11,313 shares and sold $88,985 worth of shares (4,892 units at $18.19), increasing direct ownership by 9% to 77,786 units (SEC Form 4) to cover withholding tax4 - Fortrea Holdings Inc. (0001965040) (Issuer)
- INSIDERNew insider Russell Carrie Elizabeth claimed ownership of 1,780 shares (SEC Form 3)3 - Fortrea Holdings Inc. (0001965040) (Issuer)
- INSIDERChief Executive Officer Thakral Anshul sold $2,026,284 worth of shares (111,857 units at $18.11), decreasing direct ownership by 35% to 204,940 units (SEC Form 4) (for withholding tax)4 - Fortrea Holdings Inc. (0001965040) (Issuer)
- INSIDERChief Executive Officer Thakral Anshul converted options into 416,666 shares and sold $1,913,111 worth of shares (99,869 units at $19.16) (SEC Form 4) (withholding tax)4 - Fortrea Holdings Inc. (0001965040) (Issuer)
- SECSEC Form 144 filed by Fortrea Holdings Inc.144 - Fortrea Holdings Inc. (0001965040) (Subject)
- INSIDERSEC Form 4 filed by Interim CFO Smith David Ross4 - Fortrea Holdings Inc. (0001965040) (Issuer)
- INSIDERDirector Sanders Machelle sold $174,697 worth of shares (9,700 units at $18.01), decreasing direct ownership by 21% to 36,399 units (SEC Form 4)4 - Fortrea Holdings Inc. (0001965040) (Issuer)
- SECSEC Form 144 filed by Fortrea Holdings Inc.144 - Fortrea Holdings Inc. (0001965040) (Subject)
- SECSEC Form 144 filed by Fortrea Holdings Inc.144 - Fortrea Holdings Inc. (0001965040) (Subject)
- SECSEC Form 10-Q filed by Fortrea Holdings Inc.10-Q - Fortrea Holdings Inc. (0001965040) (Filer)
- SECFortrea Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Financial Statements and Exhibits8-K - Fortrea Holdings Inc. (0001965040) (Filer)
- PRFortrea Reports Second Quarter 2026 ResultsFour consecutive quarters of execution to drive commercial, operational and financial excellence Increases full-year guidance Highlights For the three months ended June 30, 2026: Revenues of $678.2 millionBook-to-bill ratio of 1.06x, resulting in 1.12x book-to-bill for the trailing 12 monthsGAAP net loss of $(13.2) million, or $(0.14) per diluted shareAdjusted EBITDA of $58.7 millionAdjusted net income of $22.7 million, or $0.23 per diluted shareCash provided by operations of $28.9 million and free cash flow of $19.9 millionFull-year 2026 guidance increased to revenue of $2,620 million to $2,690 million and adjusted EBITDA of $205 million to $220 million DURHAM, N.C., July 29, 2026 (GL
- INSIDERDirector Smith David Ross converted options into 6,598 shares, increasing direct ownership by 22% to 36,715 units (SEC Form 4) to cover withholding tax4 - Fortrea Holdings Inc. (0001965040) (Issuer)
FTRE FAQ
5 questionsWhere does FTRE stock trade?
Fortrea Holdings Inc. (FTRE) is listed on NASDAQ.What sector and industry is FTRE in?
Fortrea Holdings Inc. operates in the Health Care sector, Medical Specialities industry.What are analysts saying about FTRE?
Fortrea Holdings Inc. has had 8 recent analyst actions on file. The most recent action was from Deutsche Bank: Buy with a $2500.00 price target on 2026-10-15. Recent price targets range from $1500.00 to $2500.00.What companies are similar to FTRE?
Notable peers in the same industry include UNH (UnitedHealth Group Incorporated), ANTM (Anthem Inc.), ELV (Elevance Health Inc.), CI (The Cigna Group), NTRA (Natera Inc.). Compare FTRE side-by-side with any of them on Quantisnow.How can I track FTRE on Quantisnow?
Quantisnow aggregates Fortrea Holdings Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow FTRE to receive live email and push alerts on every new disclosure.